Company Overview

We operate at the convergence of MedTech and HealthTech, committed to creating next-gen tools that enable early disease interception.

MedTech = Data + AI

HealthTech + Medtech =

HealthTech = Teleretinal

Request an Investor Fact Sheet

We are excited to revolutionize disease detection with point of care vital health screenings focused on oculomics.

Oculomics uses the eye as a window into the health of the whole body.

Our robust turnkey retinal screening solution allows point-of-care providers to better evaluate their patients.

  • Vitazi-MD™ is our telehealth solution.

  • Vitazi-DR ™(AI) is currently in a clinical trial in the US and used in Mexico

  • Going beyond-our platform has the potential to intercept 22 diseases

Installation of our system at primary care clinics, even pharmacies, will facilitate access and increase compliance for vital eye screenings to reduce disease burden through early disease interception. Our platform provides a range of benefits for providers such as seamless system integration, no upfront costs, additional revenue opportunities, while reducing work burden and enhancing patient care.

Market Opportunity

& Financial Projections

diabetic retinopathy market size

DR Screening Market:

Prediabetic and diabetic = $5.7B

Type 2 Diabetes Market = $1.7B

Diabetes is only our first application. It is only scratching the surface because the eye is a window to a person’s overall health. Several other eye, cardiovascular, and neurological diseases can cause changes in the eye which can be detected by oculomics through imaging and measurement techniques.

We invite you to join us in supporting this revolutionary platform

Interested in learning more?